Home page A B C D E F G H I K L M N O P Q R S T U V W X Y Z

Lunesta prescribing information

Eszopiclone (Lunesta) a new nonbenzodiazepine hypnotic agent

4.10.2017 | Logan Miers

The unique quality of eszopiclone lies in its product labeling. It is not restricted to .. Sepracor Inc. Lunesta prescribing information. Marlborough, MA:.

It is weakly bound to plasma proteins (52%–59%) ( 6 ). Peak plasma concentrations are achieved within 1 hour after oral administration. Eszopiclone is rapidly absorbed following oral administration.

No studies comparing eszopiclone with nonpharmacologic insomnia treatments or other hypnotic agents, including zolpidem and zaleplon, are currently available.

Lunesta Monograph for Professionals

9.15.2017 | Logan Miers

Lunesta reference guide for safe and effective use from the American Society of Sepracor Inc. Lunesta (eszopiclone) tablets prescribing information.

Inducers of CYP3A4: Possible decreased systemic exposure to and efficacy of eszopiclone.1.

Reduce maximum dosage because of impaired motor and cognitive performance as well as increased sensitivity to sedatives and hypnotics.1 (See Geriatric Patients under Dosage and Administration.)1.

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Not expected to alter clearance of drugs metabolized by common CYP isoenzymes.1.

HIV protease inhibitors (nelfinavir, ritonavir).

Pharmacokinetic or pharmacodynamic interactions not observed following administration of single eszopiclone dose (3 mg) with paroxetine (20 mg daily for 7 days); however, possibility of pharmacodynamic interaction following long-term concomitant use cannot be ruled out1 16 Rifampin.

Sedative and hypnotic; pyrrolopyrazine derivative; structurally unrelated to benzodiazepines.1 1 2 3 5 10 11.

Risk of next-day psychomotor impairment is increased if drug is administered with <7–8 hours of sleep time remaining, if higher than recommended dose is administered, or if used concomitantly with other CNS depressants or with drugs capable of increasing eszopiclone concentrations.1.

Rapidly absorbed following oral administration, with peak plasma concentration attained in about 1 hour.1 2 3 4.

Increased risk of complex behaviors with concomitant use of alcohol and other CNS depressants or use of the drug at doses exceeding the maximum recommended dose; however, may occur with the drug alone at therapeutic doses.1.

Importance of immediay reporting any suicidal thoughts.1.

Possible increased exposure to eszopiclone1.

Antifungals, azoles (itraconazole, ketoconazole).

Available for Android and iOS devices.

Lunesta (Sunovion) FDA Package Insert, Page 6

5.11.2017 | Logan Blare

What is the most important information I should know about LUNESTA? l your doctor about all of the medicines you take including prescription and.

See FDA-approved patient labeling ( Medication Guide ).

LUNESTA tablets should not be taken with or immediay after a meal. Patients should be counseled to take LUNESTA right before they get into bed and only when they are able to stay in bed a full night (7–8 hours) before being active again. SUNOVION. Advise patients NOT to take LUNESTA if they drank alcohol that evening.

The most common side effects of LUNESTA are:

This Package Contains 30 Tablets in 30 Blister Cards.

LUNESTA is a registered trademark of Sunovion Pharmaceuticals Inc.

Dosing Information LUNESTA (eszopiclone)

7.13.2017 | Jessica MacAdam

Read dosing information for LUNESTA for the treatment of insomnia. Prescribing Information. Prescribing Information; Medication Guide; Dosing Information.

ALVESCO, OMNARIS, and ZETONNA are registered trademarks of Takeda GmbH, used under license.

is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. SUNOVION and are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc.

Patients who experience such reactions should not be rechallenged with the drug. Rare cases of angioedema and symptoms suggesting anaphylaxis have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including LUNESTA.

Complex behaviors such as “sleep driving”, preparing and eating food, making phone calls, or having sex while not fully awake, with amnesia for the event, have been reported.

Insomnia Patient Resources LUNESTA (eszopiclone)

8.14.2017 | Jessica MacAdam

Prescribing Information; Medication Guide; Dosing Information LUNESTA (eszopiclone) is contraindicated in patients with a known hypersensitivity to.

APTIOM is under license from. LATUDA is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.

ALVESCO, OMNARIS, and ZETONNA are registered trademarks of Takeda GmbH, used under license.

ARCAPTA,, and NEOHALER are registered trademarks of Novartis AG, used under license. SEEBRI,, UTIBRON, and,, are trademarks of Novartis AG, used under license.

LUNESTA (eszopiclone) is contraindicated in patients with a known hypersensitivity to eszopiclone.